Amgen results tee up Phase III trial of Lumakras and Vectibix

17 September 2021

US biotech Amgen (Nasdaq: AMGN) could be closing in on another indication for its KRAS inhibitor Lumakras (sotorasib), which won US approval in a form of lung cancer in May of this year.

The accelerated approval made Lumakras the first approved targeted therapy for tumors with any KRAS mutation, and it is also being studied in multiple other solid tumors. This includes KRAS G12C-mutated advanced colorectal cancer (CRC) and the company has just presented results in this indication on the combination of Lumakras and Vectibix (panitumumab), the firm’s monoclonal antibody epidermal growth factor receptor (EGFR) inhibitor.

These are the first combination study results from the Phase Ib/II CodeBreaK 101 study, the most comprehensive global clinical development program in patients with KRAS G12C-mutated CRC. These encouraging results included an objective response rate (ORR) of 27% among 26 patients in the efficacy analysis set, which included five patients who had progressed with prior sotorasib monotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK